AR

Ashis Ranjan Das

Director Director DIN 00209471
DIN 00209471 First appointment Dec 1982 Primary industry Healthcare
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Dec 1982
Shareholding value β€’β€’β€’β€’ Premium profile

About Ashis Ranjan Das

Data last updated:

Ashis Ranjan Das was a Director at Neo Bacto Clinical Laboratories Pvt Ltd (1982–2022) and Director at Pharm India Pvt Ltd (from 1983). The companies operate in Healthcare.

DIN 00209471
Primary Designation Director
Industry Healthcare
First Appointment 31 Dec 1982
Oldest Company Age 43 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director31 Dec 19821982₹73.5 Lakh (FY 2025)Active
Pharm India Pvt Ltd U51109WB1983PTC036708
Director26 Aug 19831983Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Pharm India Pvt Ltd
Neo Bacto Clinical Laboratories Pvt Ltd
Premium access

Shareholding and investment profile for Ashis Ranjan Das

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ashis Ranjan Das

Ashis Ranjan Das was first appointed on 31 Dec 1982 as Director at Neo Bacto Clinical Laboratories Pvt Ltd. The most recent appointment on record is 26 Aug 1983 at Pharm India Pvt Ltd.

Ashis Ranjan Das held 2 earlier board appointments: Neo Bacto Clinical Laboratories Pvt Ltd (Director, 31 Dec 1982 to 25 Jan 2022); Pharm India Pvt Ltd (Director, from 26 Aug 1983).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available